A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Brief description of study
If you have been diagnosed with metastatic melanoma that has gotten worse after previous treatment, you may qualify for this phase II study evaluating the investigational drug LN-144. The main goal of this study is to find out if study drug LN-144 is safe for patients with metastatic melanoma.
Clinical Study Identifier: s16-00804
ClinicalTrials.gov Identifier: NCTs16-00804
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
